Arbutus Biopharma
ABUS
88 hedge funds and large institutions have $227M invested in Arbutus Biopharma in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 9 closing their positions.
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
44% more capital invested
Capital invested by funds: $158M → $227M (+$69.1M)
24% more funds holding
Funds holding: 71 → 88 (+17)
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
15% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $1.58M
3.03% more ownership
Funds ownership: 40.32% → 43.35% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.94M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$3.67M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$3.41M |
| 5 |
Morgan Stanley
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$10.7M |
| 2 |
D.E. Shaw & Co
New York
|
-$4.07M |
| 3 |
Goldman Sachs
New York
|
-$2.61M |
| 4 |
Renaissance Technologies
New York
|
-$2M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.78M |
ABUS Hedge Fund Activity: Q3 2018 in Review
88 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2018, worth a combined $227M — up 44% from $158M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ABUS positions and 9 closed out — a net gain of 17 holders — while 25 added to existing stakes and 21 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $12.2M. The largest seller was RTW Investments, cutting an estimated $10.7M.
- 88 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2018, up from 71 in Q2 2018.
- Funds reported $227M of Arbutus Biopharma stock for Q3 2018, up 44% quarter-over-quarter.
- 26 funds opened new Arbutus Biopharma positions in Q3 2018 and 9 closed out, a net change of +17 holders.
- The largest Arbutus Biopharma buyer in Q3 2018 was EcoR1 Capital, an estimated $12.2M added.
- The largest Arbutus Biopharma seller in Q3 2018 was RTW Investments, an estimated $10.7M sold.
Based on aggregated 13F filings for Q3 2018.